XenoPort, Inc. · Santa Clara, CA United States (NASDAQ: XNPT)
| 3410 Central Expwy. | Phone: 408-616-7200 |
| Santa Clara, CA | Fax: 408-616-7210 |
| 95051 | |
| United States | 
Map This Company |
XenoPort, Inc. Rankings
Company Description
XenoPort sounds like something straight out of science fiction, but there's nothing fictional about XenoPort's job of improving drugs' ability to be absorbed by tissues in the body. The development firm uses genomics to identify transporter proteins. It then designs oral drug molecules to find and ride these transporters through the gastrointestinal tract to their destination. XenoPort began marketing its first drug in 2011 when it received FDA approval for its gabapentin enacarbil candidate, Horizant, to treat restless legs syndrome (RLS). XenoPort markets Horizant in the US with
XenoPort, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: XNPT Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 108 |
Executives
20 executives listed for XenoPort, Inc.'s Santa Clara, CA location.
| CEO and Director | Ronald Barrett | |
|---|---|---|
| SVP Finance and CFO | William Harris | |
| SVP and Chief Commercialization Officer | Vincent Angotti |